A unique drug may change the treatment of influenza
Johnson & Johnson has carried out a second phase of testing of its experimental drug against the influenza virus. The studies have shown that the drug significantly reduced the viral exposure to people with influenza. The code name of the drug is Pimodivir. The major task is to help patients who are resistant to treatment by standard methods, as well as patients hospitalized with influenza
According to "Remedium", the study evaluated the efficacy of the new drug for monotherapy and for concomitant use with oseltamivir. The drug was tested in patients with acute uncomplicated seasonal flu.
Pimodivir is the first-in-class inhibitor of PB2 polymerase subunit of influenza A virus. This new mechanism of activity allows the drug to be used when the virus does not respond to standard drugs.